Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Decreases By 44.2%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large drop in short interest in June. As of June 15th, there was short interest totaling 9,143 shares, a drop of 44.2% from the May 31st total of 16,388 shares. Based on an average daily volume of 19,697 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent reporting period. 15.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Xenetic Biosciences Price Performance

XBIO traded down $0.01 during trading hours on Wednesday, reaching $2.90. The company’s stock had a trading volume of 51,208 shares, compared to its average volume of 18,469. The stock has a market cap of $6.64 million, a PE ratio of -2.37 and a beta of 2.19. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93. The business’s 50-day moving average is $3.06 and its 200-day moving average is $2.71.

Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The business had revenue of $0.81 million for the quarter.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.